Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationBone Marrow TransplantationTransplantation, AutologousBone MarrowGraft vs Leukemia EffectTransplantation ChimeraBone Marrow CellsPeripheral Blood Stem Cell TransplantationTissue DonorsTreatment OutcomeMyeloablative AgonistsBusulfanHistocompatibilityGraft vs Tumor EffectWhole-Body IrradiationLeukemiaChimerismRecurrenceHistocompatibility TestingStem CellsRetrospective StudiesGraft SurvivalHematologic DiseasesVidarabineAllograftsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesCord Blood Stem Cell TransplantationMyeloid CellsLymphocyte TransfusionSiblingsHLA AntigensRemission InductionImmunosuppressive AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaHepatic Veno-Occlusive DiseaseSurvival RateHematopoiesisCytomegalovirus InfectionsTime FactorsSurvival AnalysisAnemia, AplasticAcute DiseaseLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTransplantation ImmunologyT-LymphocytesCombined Modality TherapyLeukemic InfiltrationFlow CytometryTransplantation, IsogeneicDisease-Free SurvivalMultiple MyelomaMice, Inbred C57BLCystitisLymphocyte DepletionAntigens, CD34Bone and BonesMinor Histocompatibility AntigensCell DifferentiationOpportunistic InfectionsHematopoietic Stem Cell MobilizationSevere Combined ImmunodeficiencyNeoplasm, ResidualCyclophosphamideFollow-Up StudiesLymphoproliferative DisordersSalvage TherapyAntilymphocyte SerumCytomegalovirusLeukemia, MyeloidBronchiolitis ObliteransLiver TransplantationRisk FactorsImmunocompromised HostPrognosisBlood Group IncompatibilityImmunosuppressionCell LineagePrimary MyelofibrosisMycosesPhotopheresisFatal OutcomeMesenchymal Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsCells, CulturedColony-Forming Units AssayFetal BloodSurvivorsGanciclovirCell TransplantationCytarabineThymus GlandUnrelated DonorsBone Marrow Diseases